2016-04-25 19:28:52 UTC

New Recommendation: H. Pylori Therapies Should Be Given for 14 Days

April 26, 2016

The Toronto Consensus for the treatment of H. Pylori, published in Gastroenterology, stresses careful attention to local antibiotic resistance and eradication patterns.

Helicobacter pylori (H. pylori) infection is increasingly difficult to treat. Due to the increasing prevalence of antibiotic-resistant strains and evidence of more frequent failures of triple therapies — as well as the existence of new therapies — the Canadian Association of Gastroenterology and the Canadian Helicobacter Study Group determined that an updated consensus statement was needed.

This new consensus statement — now available as a Gastroenterology article in press — reviews the literature and provides specific, updated recommendations for eradication therapy in adults.

In the statement, the authors conclude that optimal treatment of H. pylori requires careful attention to local antibiotic resistance and eradication patterns. Based on evidence of higher eradication with regimens of longer duration, and increasing failure of shorter treatment durations, the consensus group strongly recommended that all H. pylori eradication regimens be given for 14 days.

The group also states that concomitant non-bismuth quadruple therapy or traditional quadruple bismuth therapy should play a more prominent role in H. pylori eradication.

Read the full recommendations in Gastroenterology (login required). 

More on Helicobacter pylori Infection

Effects of Community Screening for Helicobacter pylori: 13-Year Follow-Up Evaluation of a Randomized Controlled Trial

Oct. 22, 2017

This randomized clinical trial with 13 years of follow-up evaluation, designed to provide evidence on the effect of H pylori population screening, showed no significant long-term effect when compared with usual care in this low-prevalence area.

Submucosal Tumor of the Stomach With Drastic, Short-Term Changes in Morphology

Aug. 10, 2017

What caused the lesion in a man diagnosed with a submucosal tumor in the upper gastric corpus, to change to a reddish, semipedunculated tumor with blood oozing on the surface?

Clinical Manifestations of Helicobacter pylori–Negative Gastritis

June 22, 2017

We found that H pylori–negative gastritis was present in approximately 18% of patients with gastritis.